What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

View Full Paper

Ask AI

Bookmark

Authors

Final analysis shows recombinant ADAMTS13 improves treatment effectiveness and safety while reducing adverse events in cTTP patients.

No acute TTP events occurred during prophylaxis with recombinant ADAMTS13, indicating its effectiveness.
The mean annualized event rate of adverse events was lower for ADAMTS13 compared to plasma-based therapy.
This was a phase 3 randomized controlled study involving patients with congenital thrombotic thrombocytopenic purpura.
Findings highlight the potential of ADAMTS13 prophylaxis to enhance treatment satisfaction without new safety concerns.

Windyga et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark